United States securities and exchange commission logo





                             October 15, 2021

       Lindsay A. Rosenwald, M.D.
       Chief Executive Officer
       Fortress Biotech, Inc.
       2 Gansevoort Street, 9th Floor
       New York, NY 10014

                                                        Re: Fortress Biotech,
Inc.
                                                            Post-Effective
Amendment No. 1 to Form S-3
                                                            Filed October 6,
2021
                                                            File No. 333-255185

       Dear Dr. Rosenwald:

              We have reviewed your post-effective amendment and have the
following comment. In
       our comment, we may ask you to provide us with information so we may
better understand your
       disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Post-Effective Amendment No. 1 to Form S-3 filed October 6, 2021

       General

   1.                                                   We note that you have
omitted substantially all of the disclosure required by Part I of
                                                        Form S-3. Please amend
to include all of the disclosures required by Part I of Form S-3.
                                                        Refer to Securities Act
Rule 472(b).
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Lindsay A. Rosenwald, M.D.
Fortress Biotech, Inc.
October 15, 2021
Page 2

      Please contact Christine Westbrook at 202-551-5019 or Celeste Murphy at
202-551-
3257 with any questions.



                                                        Sincerely,
FirstName LastNameLindsay A. Rosenwald, M.D.
                                                        Division of Corporation
Finance
Comapany NameFortress Biotech, Inc.
                                                        Office of Life Sciences
October 15, 2021 Page 2
cc:       Mark F. McElreath, Esq.
FirstName LastName